Envveno medical participates in a new virtual investor "what this means" segment to discuss how president trump's recent cvi diagnosis may impact the company

- envveno is developing the venovalve as a potential treatment option for the approximately 2.5 million patients in the u.s. suffering from severe deep chronic venous insufficiency - fda decision expected in 2h'2025 - access the "what this means" segment here irvine, ca / access newswire / august 4, 2025 / envveno medical corporation (nasdaq:nvno) ("envveno medical" or the "company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a virtual investor "what this means" segment entitled, "envveno medical - making veins work again - how president trump's cvi diagnosis is raising awareness." rob berman, ceo and dr. marc glickman, cmo of envveno medical discussed the progressive nature of chronic veinous insufficiency and whether president trump may one day be a candidate for the venovalve® following u.s. food and drug administration (fda) approval.
CVI Ratings Summary
CVI Quant Ranking